We would love to hear your thoughts about our site and services, please take our survey here.
While Science Day has shown that AVA6000 avoids cardio toxicity in patients, we investors are all suffering from heart palpitations. Can we look forward to a recovery anytime soon?
Yes that’s the point. The algorithm produces an inaccurate result.
I had a small top up this morning and bought 488 shares which are showing yet again wrongly as a sell. When is LSE / AIM going to sort this out? The notion that the difference between a buy and a sell can be determined by assessing whether the price paid is above or below the average of the prevailing buy and ask is ludicrous and inaccurate. In this day and age surely it can’t be beyond the dimmest software engineer to link the definitive buy or sell instruction to the data that’s reported.
What I can’t understand is why Conifer haven’t increased their stake. As an early institutional investor with an astute track record they must be watching the progress of the clinical trial and coming to the same conclusions as the rest of us.
Surely the key issue is not lab space. It’s proximity to the Royal Marsden as the lead institution in the current and upcoming clinical trials - 40 minutes drive away instead of 90 minutes from Cambridge. Add to that Imperial’s research expertise and Takeda’s on site presence it’s been a very smart move.
Well I had been keeping quiet because of the trolls but now that this thread has surfaced, this is what I sent to Jupiter on Tuesday:
Dear Jupiter,
As a believer in free markets, I feel that Jupiter has every right to short any company it chooses. But surely Jupiter has a corporate conscience and to short Avacta, a company with breakthrough cancer therapies in clinical trials, really takes the biscuit?
Those of us making investments based on the benefit to mankind are appalled at your company’s actions - many good-hearted people have lost their life savings as Jupiter has pushed the Avacta share price to rock bottom.
I would appeal to the good folk at Jupiter to close your shorts and let the management team do their thing without pi sniping and despair. You never know one day you guys and gals at the trading desks might need chemotherapy treatment and be grateful for Avacta’s pre|CISION platform technology (first off is prodoxorubicin). Simply put, it targets the tumour not the heart and by so doing it alleviates the horrendous side-effects of chemotherapy. By reducing systemic toxicities and adjusting the dose it’s going to be a game changer for cancer treatment worldwide.
Instead of shorting Avacta, may I suggest that Jupiter supports the company by positive investment leading to an increase in the sp and market cap. IMHO Big Pharma will step in to acquire the company once performance data is formally released this summer and Jupiter could make a fortune!
Yours sincerely
Although we long-suffering LTHs are anxiously awaiting a RNS from Avacta, isn’t it more likely that initial news regarding the study to evaluate the safety, pharmacokinetics and early efficacy of AVA6000 in solid tumours is more likely to be announced by one of the Principle Investigators Professor Chris Twelves, Professor Udai Banerji and Dr Natalie Cook at the three testing sites rather than Avacta as sponsor? If so that news could come at any time of day dependent upon priorities dictated by patients in desperate need of medical care. If my investment results in improved outcomes for these and future patients it’s been worth every penny!
Thank you Oph and MrA, that’s helpful.
The FDA approval to undertake a clinical trial in the US would imply that early results have been positive at the three UK sites Royal Marden London, St James Leeds and the Christie Manchester. If that’s the case why aren’t the three other locations Glasgow, Newcastle and Sheffield still showing as ‘Not yet recruiting’? Does anybody know? I would have thought that the knowledge obtained from the initial trials would have been shared across all six approved sites and that those sites yet to participate would be doing everything possible to offer a breakthrough remedy to their critically ill patients. Or is this a function of the 3 + 3 design and this constrains the cohorts?
Those after hours trades at £2 in auction are massive! Anybody know what’s going on? Or do we have to wait until the RNS at 7am?
This is my effort for what it’s worth:
Dear Sir Chris Wormald,
I am writing this letter to express my deep concerns as to why we are not using Lateral Flow Tests (LFTs) made in the UK instead of poor-quality tests made in the People’s Republic of China, the original source of this global epidemic which so far has claimed 5.4m lives.
The tests produced in the UK have secured the CE mark but have been prevented from sale since 1st November by the UK regulatory authorities imposing a ‘desktop review’ to which the Chinese versions purchased by the DHSC are exempt. Having submitted all the necessary documentation under the CDTA regulations by 1st September and paid the administration fee, only 14 products have been approved (5 from Turkey, 4 USA, 2 Germany 3, 3 UK) and they are all PCR tests. None are LFTs and the review process which should take 20 days has now passed the 120 day mark!
Why has the government spent £bns on LFTs from China when it could have supported the UK diagnostic industry? How much have we spent on Chinese tests such as the one branded as Innova which the FDA insisted should be withdrawn from the market and any stocks be put in the ‘garbage’?
Why has the DHSC / UKHSA allowed Porton Down to impose UK regulations using frozen covid samples which benefit less sensitive Chinese tests which detect the N protein and by so doing eliminate the more advanced LFT which detects the S protein produced by Avacta, a UK company with diagnostic and therapeutic divisions with breakthrough cancer treatments currently in clinical trials? No one I know has a frozen nose!
Why was Omega Diagnostics given a £360m contract and loaned equipment by the government but for it never to be enacted? Was it right that the necessary staff were recruited, trained and then made redundant?
And why is Abingdon Health owed £6m by the DHSC for goods supplied but not paid for?
The Prime Minister’s promises of a ‘Moonshot’, ‘Working night and day to build a UK diagnostics industry’ and ‘Build back Better’ have all failed to materialise.
The British government surely should give priority to our industries in the UK to help our economy, create jobs and support our science base.
Bearing in mind that Mr Ken McCallum, the head of MI5 only recently warned against the big challenges presented by China, I appeal to you to change government policy so that in future it ‘Buys British’ to protect our economic independence and ability to identify biohazards.
Yours sincerely
Along with a pack of Flowflex LFTs today I received a PCR test with a pamphlet entitled ‘Participant information sheet for rapid lateral flow test evaluation’ from NHS Test and Trace. It says ‘We have sent you a PCR test in addition to your rapid lateral flow tests as part of an ongoing evaluation of rapid test performance. As we continue to send out home-based rapid lateral flow tests we need to understand how effective the rapid lateral flow tests are at finding positive cases in different settings. To do that we are asking you to take part in an ongoing evaluation by completing and returning a PCR test. This is in addition to your rapid lateral flow test so we can compare results from these two methods.’
What’s this all about? What are they up to? Have they finally realised that the Chinese tests are highly inaccurate?
I’ve had 8 emails from the DHSC this evening which in each case spells Omicron incorrectly as OMCIRON. Don’t they ever check their work?
The UKHSA and DHSC have just updated the list of validated products. Leaving aside the fact that no LFT devices have been approved as yet, the list comprises 3 from the US, 1 from Germany, 4 from Turkey and just 1 from the UK. Whatever happened to building a home diagnostic industry? I despair!
Muck165/JSP123,
The other option which the Board might consider would be Factoring or its lower cost equivalent Invoice Discounting. With significant sales revenue in prospect, cash would be released to the company based upon the value of its debtor book. This would help to avoid a placing and the dilution of existing shareholders. Or how about an old fashioned bank loan secured against the accounts receivable?
UKHSA / DHSS have just updated the web page and there’s still just three approved tests and all with a US address. Absolute madness!!!
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
So they’ve only approved three tests and each one carries a US address! With that in mind I think we should all ‘Report a problem with this page’. I certainly have!
https://www.gov.uk/government/publications/covid-19-test-validation-approved-products
This bulletin just published is all very thorough but will the DHSC continue to supply Chinese rubbish or will they at long last favour high quality tests made in the UK?
https://www.gov.uk/government/publications/workplace-testing-terms-and-conditions
A third location is now recruiting for the AVA6000 trial:
https://www.clinicaltrials.gov/ct2/show/NCT04969835